Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 36
- 试验地点
- 2
- 主要终点
- Liver Stiffness Measured by Velacur
研究概览
简要总结
The purpose of this study is to prospectively evaluate the utility of Liver Incytes in assessing NAFLD with or without advanced fibrosis in patients seen in liver clinics for suspected NAFLD diagnosis.
详细描述
The proposed study will evaluate the performance characteristics of LSM as a measure of fibrosis and ACE as a measure of hepatic steatosis by Liver Incytes in patients with different stages of NAFLD. In addition, the diagnostic accuracy of ACE will be compared to CAP and LSM as measured by Liver Incytes to that measured by FibroScan® using liver histology as the reference standard. The performance of these two methods will also be compared to that of non-invasive blood based markers such as APRI, FIB4, and NAFLD fibrosis score in predicting advanced fibrosis in biopsy proven NAFLD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
盲法说明
This is an open label study in that all participants will receive the same study procedures.
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged 21 years or older
- •Suspected NAFLD or NASH with plans to undergo standard of care liver biopsy
- •History of biopsy proven NAFLD or NASH within 6 months prior to enrollment
- •Planned liver biopsy for evaluation of NAFLD within 6 months of enrollment
- •Ability to provide informed consent
排除标准
- •Fasting for less than three hours prior to the scan
- •Subject is a pregnant or lactating female
- •Subject with current, significant alcohol consumption or history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening. Significant alcohol consumption is defined as more than 20 gram per day in females and more than 30 grams per day in males, on average (a standard drink in the US is considered to be 14 grams of alcohol).
- •Subject is unable to reliably quantify alcohol consumption based upon local study physician judgment.
- •Subject uses drugs historically associated with NAFLD (amiodarone, methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at doses greater than those used for hormone replacement, anabolic steroids, valproic acid, and other known hepatotoxins) for more than 2 weeks in the year prior to screening
- •Subject with history of cirrhosis or clinical evidence of hepatic decompensation as defined by the presence of any of the following abnormalities at screening
- •Serum albumin less than 3.5 grams/deciliter (g/dL).
- •INR greater than 1.
- •Direct bilirubin greater than 1.3 milligrams per deciliter (mg/dL).
- •Subject has a history of bleeding esophageal varices, ascites or hepatic encephalopathy
- •Subject has history of other forms of chronic liver diseases such as viral hepatitis, autoimmune hepatitis, cholestatic liver disease (primary biliary cirrhosis or primary sclerosing cholangitis).
- •Subject with active substance abuse
- •Acute hepatitis defined as AST/ALT > 500 U/L
- •Patients with a pacemaker or defibrillator
结局指标
主要结局
Liver Stiffness Measured by Velacur
时间窗: one day
Assessing correlation of liver stiffness measurements (LSM) as measured by Velacur to grade of fibrosis on liver histology of patients with NAFLD who underwent standard of care liver biopsy. Results are reported per fibrosis category: F0, F1, F2, F3, and F4.
Liver Stiffness Measured by Transient Elastography
时间窗: one day
Assessing correlation of liver stiffness measurements (LSM) as measured by FibroScan to grade of fibrosis on liver histology of patients with NAFLD who underwent standard of care liver biopsy. Results are reported per fibrosis category: F0, F1, F2, F3, and F4.
次要结局
未报告次要终点
研究者
Samer Gawrieh
Professor of Clinical Medicine
Indiana University